Author: medpointepharma

articles

MedPointe Pharmaceuticals: Cold & Cough Relief Products 10

Post author By medpointepharma
Post date July 25, 2022

Prescribing Information

Please click to view and download the Cold Symptom Relief Guarantee document (Adobe PDF)

articles

MedPointe – Management 2

Post author By medpointepharma
Post date July 20, 2022

John T. W. Hawkins
Executive Vice President, Corporate Development and External Affairs

John Hawkins, Executive Vice President, Corporate Development and External Affairs of MedPointe, is a co-founder of MedPointe Capital Partners, LLC.

He brings a distinguished background in the healthcare and financial industries spanning 20-plus years. From 1990-2000, John was the Managing Director and Global Sector Leader (Healthcare) of Russell Reynolds Associates, Inc., a leading international executive search firm. Most recently, he also directed the firm’s activities within the Board of Director and corporate governance arenas.

Earlier in his career, Mr. Hawkins was Senior Vice President and Chief Financial Officer of Invitron Corp., a mammalian cell culture manufacturing company spun out in an IPO from Monsanto in 1987, and prior thereto, was a Vice President of Investment Banking with Alex. Brown & Sons.

Mr. Hawkins is a graduate of the University of Virginia. He serves on the Board of Trustees of the Jefferson Scholars Foundation and is a member of the Board of Managers of the UVA Alumni Association. He received an M.B.A. degree from the Amos Tuck School of Business Administration at Dartmouth College.

articles

MedPointe Pharmaceuticals: Cold & Cough Relief Products 2

Post author By medpointepharma
Post date July 15, 2022

Safety/Indication

Adverse reactions may include drowsiness, sedation, dryness of mucous membranes, and gastrointestinal effects.

* When used for symptomatic relief of nasal congestion and dry, nonproductive cough associated with the common cold, sinusitis, and other respiratory allergies. Appropriate therapy should be provided for the primary disease.

� When used for symptomatic relief of coryza and nasal congestion associated with the common cold, sinusitis, allergic rhinitis, and other upper respiratory tract conditions. Appropriate therapy should be provided for the primary disease.

� When used for symptomatic relief of cough associated with respiratory tract conditions such as the common cold, bronchial asthma, and acute and chronic bronchitis. Appropriate therapy should be provided for the primary disease.

� TUSSI-12�D is supplied as TUSSI-12�D S Suspension.

Please see enclosed full Prescribing Information.

articles

Meda Pharmacueticals Inc. – Contact Us

Post author By medpointepharma
Post date July 14, 2022

Directions to the Meda Pharmaceuticals headquarters in Somerset, New Jersey

Meda Pharmaceuticals

265 Davidson Ave., Suite 300

Somerset, NJ 08873-4120

From the New Jersey Turnpike:

Use Exit 10

Follow I-287 north and refer to (From I-287 Traveling North) below.

From I-287 traveling South:

Proceed to exit 10 (Route 527/ Easton Avenue / New Brunswick). At the bottom of the exit ramp get immediately into the left lane and make a left turn. Go under the overpass of I-287.
Once you have turned left, proceed straight (bearing to your right – 527 North.
Turn left at the first traffic signal onto Davidson Avenue.
Proceed on Davidson Avenue for approximately � mile and 265 will be on the right, just past the Hampton Inn.

From I-287 Traveling North:

Proceed to exit 10 (Route 527/ New Brunswick / South Bound Brook.) Follow Route 527 (Easton Avenue) to the first traffic light and make a left on to Davidson Avenue.
Proceed on Davidson Avenue for approximately � mile and 265 will be on the right, just past the Hampton Inn.

From Rt. 18 North:

As you travel through New Brunswick on Rt. 18 North take the Easton Ave. Exit.
Continue on to the traffic signal and make a left turn onto Landing Lane.
Continue on to the next traffic signal and make a right turn onto Easton Ave (527).
Follow Easton Ave (527) for approximately 4 miles. After crossing under I-287, turn left at the next traffic signal onto Davidson Avenue.
Proceed on Davidson Avenue for approximately � mile and 265 will be on the right, just past the Hampton Inn.

articles

MedPointe – Corporate Mission

Post author By medpointepharma
Post date July 7, 2022

articles

MedPointe – Management 7

Post author By medpointepharma
Post date July 1, 2022

Richard N. Spivey, PharmD, PhD

Senior Vice President, Research and Development

Richard N. Spivey, PharmD, PhD, Senior Vice President, Research and Development oversees the Company’s worldwide medical, regulatory, product/process development, and quality assurance programs. He brings to MedPointe an outstanding background in pharmaceutical product development and regulatory affairs spanning more than twenty years at leading pharmaceutical companies, including most recently Pharmacia/Searle, and earlier, Warner-Lambert and Schering-Plough. In his most recent position (2001-2002) at Pharmacia Corp., he reported to the corporation’s CEO as its SVP-Corporate Technical Policy. Immediately prior thereto and upon Searle’s merger into Pharmacia in 2000, Dr. Spivey was named SVP-Global Regulatory Affairs at Pharmacia, where he led the combined company’s worldwide regulatory activities, including direct oversight of 250 staff at three R&D locations and several development centers. At Searle, as VP-WW Regulatory Affairs (1996-2000), he steered the strategic regulatory development of Searle’s portfolio, including the filing, labeling and global approval of its arthritis medication, Celebrex, and its follow-up compound, Bextra. His regulatory experience includes extensive interaction with the world’s most influential pharmaceutical regulatory agencies; e.g., FDA, HPB, EMEA, CPMP, and TGA. While at Pharmacia, he also served as Chairman of the Pharmaceutical Research and Manufacturers of America’s (PhRMA) Regulatory Affairs Committee.

From 1990-1996, Dr. Spivey served in a series of successively more senior Regulatory Affairs positions at Warner-Lambert (1990-1992) and Schering-Plough (1993-1996). He began his business career in 1985 as a Clinical Investigation Manager at Boehringer Ingelheim where he led several Phase IV research programs.

Prior to his career in the pharmaceutical industry, Dr. Spivey was engaged in various academic pursuits, including an assistant professorship at the College of Pharmacy at Washington State University and a Research Associate post at Tufts’ Center for the Study of Drug Development.

Dr. Spivey obtained his PharmD from the University of Southern California and earned his PhD in Pharmacy Administration from the University of Minnesota.

articles

MedPointe – Compliance

Post author By medpointepharma
Post date June 28, 2022

articles

MedPointe – Management

Post author By medpointepharma
Post date June 19, 2022

articles

MedPointe – Management 1

Post author By medpointepharma
Post date June 17, 2022

James S. Burns

Co-Founder

James S. Burns, a co-Founder of MedPointe and former MedPointe President, retired from the Company in November 2003, after having served over MedPointe’s first two years as one of its principal executives. Prior to MedPointe’s

completion of the leveraged buyout of the Healthcare Business of Carter-Wallace Inc., Mr. Burns was a co-Founder of MedPointe Capital Partners, LLC, the private equity group that identified the acquisition target and arranged for its $500 million financing. His contributions were vital to the formation of the Company and to its early success as an emerging specialty pharmaceutical company. He remains a substantial shareholder in the Company.

Prior to founding MedPointe, Mr. Burns was Vice Chairman of HealthCare Investment Corporation; Founder, Chairman and CEO of Osiris Therapeutics, Inc.; a Group President of Becton, Dickinson and Company; and a Partner at Booz-Allen & Hamilton, Inc.

Mr. Burns is Vice Chairman of the Maryland Technology Development Corporation, a Trustee of the University of Maryland Biotechnology Institute and a Director of the American Type Culture Collection. He earned his B.S. and M.S. degrees in Biological Sciences from the University of Illinois and an MBA degree from DePaul University.